STVN:NYE-Stevanato Group SpA (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 19.97

Change

0.00 (0.00)%

Market Cap

USD 5.45B

Volume

0.41M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-2.04 (-0.86%)

USD 68.18B
ALC Alcon AG

-0.12 (-0.13%)

USD 44.55B
HYB New America High Income Closed..

-0.02 (-0.27%)

USD 35.93B
RMD ResMed Inc

+1.64 (+0.90%)

USD 30.24B
WST West Pharmaceutical Services I..

-7.40 (-2.24%)

USD 24.60B
BAX Baxter International Inc

-0.23 (-0.67%)

USD 17.42B
TFX Teleflex Incorporated

-2.11 (-1.05%)

USD 9.81B
ATR AptarGroup Inc

-1.86 (-1.27%)

USD 9.72B
BLCO Bausch + Lomb Corp

-0.05 (-0.33%)

USD 5.25B
HAE Haemonetics Corporation

-2.31 (-2.69%)

USD 4.34B

ETFs Containing STVN

ZEB:CA BMO S&P/TSX Equal Weight .. 17.24 % 0.60 %

+0.01 (+0.00%)

CAD 3.65B
BNC:CA 13.14 % 0.68 %

N/A

N/A
BANK:CA Evolve Canadian Banks and.. 12.57 % 0.39 %

+0.03 (+0.00%)

CAD 0.18B
ZWB:CA BMO Covered Call Canadian.. 11.69 % 0.71 %

+0.04 (+0.00%)

CAD 2.85B
HCB:CA 6.95 % 0.65 %

N/A

N/A
XDV:CA iShares Canadian Select D.. 6.01 % 0.55 %

-0.18 (0.00%)

CAD 1.52B
BFIN-U:CA 5.72 % 0.00 %

N/A

N/A
QXM:CA First Asset Morningstar N.. 4.97 % 0.58 %

+0.07 (+0.00%)

CAD 0.07B
PDC:CA Invesco Canadian Dividend.. 4.24 % 0.55 %

-0.08 (0.00%)

CAD 0.74B
XFN:CA iShares S&P/TSX Capped Fi.. 4.03 % 0.61 %

-0.21 (0.00%)

CAD 1.36B
WXM:CA First Asset Morningstar C.. 3.45 % 0.67 %

+0.14 (+0.00%)

CAD 0.54B
MCLC:CA Manulife Multifactor Cana.. 3.40 % 0.45 %

+0.01 (+0.00%)

CAD 0.31B
XCG:CA iShares Canadian Growth 3.31 % 0.55 %

-0.17 (0.00%)

CAD 0.08B
FBE:CA 2.65 % 0.83 %

N/A

N/A
DXIF:CA Dynamic Active Internatio.. 0.00 % 0.00 %

N/A

CAD 4.83M

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.82% 11% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.82% 11% F 5% F
Trailing 12 Months  
Capital Gain -25.21% 17% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.21% 17% F 8% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 21.62% 83% B 85% B
Dividend Return 21.62% 83% B 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.62% 44% F 25% F
Risk Adjusted Return 53.23% 89% A- 75% C
Market Capitalization 5.45B 56% F 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.